logo-loader

Vaccines worries hit GSK

Published: 19:59 28 Oct 2026 AEDT

GSK PLC - Vaccines worries hit GSK

Drugs giant GSK PLC (LSE:GSK, NYSE:GSK) has slipped despite beating forecasts, with investors focused on falling vaccine sales and a guarded profit outlook

GSK shares fell 4% to 1,852p in early trading, after the FTSE 100 drugmaker's third-quarter results beat expectations on sales and core earnings.

Sales of £8.9 billion were in line with the consensus forecast, according to Jefferies, which compiled the figures using Visible Alpha data.

Core operating profit of £3.1 billion was 5% ahead, helped by a better gross margin and lower selling and administration costs.

Core earnings per share of 54.6p beat the consensus figure of 50.3p by 9%, with a lower tax rate also helping.

The weak spot was vaccines, where sales of £2.58 billion missed forecasts of £2.61 billion.

GSK reaffirmed its 2026 guidance, but core earnings per share growth is still expected only in the lower half of its 7% to 9% range.

That is despite royalty income now being expected at the top of its range, at about £900 million, and lower interest charges of £700 million to £750 million, down from £800 million.

Jefferies said consensus sits about 50 basis points below the midpoint of the implied range. The broker rates the shares at "buy" with a price target of 2,500p.

Parbo Resources uncovers new greenstone belt at Mount Padbury

Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone beneath previously mapped granite at the GoldenEye prospect, from just 44 metres...

5 hours, 44 minutes ago